Evidence map›Paper›PMID 37088953›Full record

SynthesisCNS neuroscience & therapeutics2023

Repetitive transcranial magnetic stimulation may be superior to drug therapy in the treatment of Alzheimer's disease: A systematic review and Bayesian network meta-analysis.

Naili Wei, Haoxin Liu, Wenrui Ye, Shengliang Xu, Changhao Lu, Anxiang Dai, Ting Hou, Xin Zeng, Jie Wu, Jian Chen

Open access · goldAbstract readSystematic ReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in CNS neuroscience & therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Naili WeiDepartment of Neurosurgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Haoxin LiuDepartment of Neurosurgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Wenrui YeDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Shengliang XuDepartment of Neurosurgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Changhao LuDepartment of Neurosurgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Anxiang DaiDepartment of Neurosurgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Ting HouDepartment of Neurosurgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Xin ZengDepartment of Geriatrics, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Jie WuDepartment of Neurosurgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.ORCID 0000-0002-6039-9119
Jian ChenDepartment of Neurosurgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.ORCID 0000-0003-4014-6357
Shantou University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRepetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation therapy that is primarily used to treat a variety of neuropsychiatric conditions. Recently, previous research reports stated that rTMS have the characteristics of neurorestorative in Alzheimer's disease (AD). However, the relevant clinical research evidence has not been fully summarized.

methodsThis article performed a network meta-analysis of individual participant data from eligible studies searched in PubMed, Embase, and the Cochrane Library from inception to March 31, 2022. The drug treatments involved were acetylcholinesterase inhibitors (AChEIs), N-methyl-d-aspartate (NMDA), anti-amyloid-beta (Aβ), and some new targeted therapeutic drugs.

resultsA total of 15, 548 individuals with AD disease in 57 randomized clinical trials (RCTs) were included in this meta-analysis. The results indicated that the patients who received rTMS treatment (standard mean difference [SMD]: 0.65; 95% confidence interval [CI]: 0.22-1.07) had a better MMSE score than placebo. Treatment outcome analysis showed that, compared with multiple pharmacological interventions, rTMS acquired the greatest probability rank with the best cognitive improvement in MMSE score [the surface under the cumulative ranking curve (SUCRA) 93.3%] and ADAS-cog score (SUCRA 86.7%). At the same time, rTMS treatment had the lowest rank in the adverse events (SUCRA 24.1%) except for the placebo group (SUCRA 19.1%).

conclusionCompared with the current clinical drug treatment, rTMS demonstrated better cognitive function improvement and fewer adverse events in AD patients. Therefore, rTMS shows broad prospects in the treatment of Alzheimer's disease, and it is worth being widely popularized in clinic.

Indexed as

Alzheimer DiseaseTranscranial Magnetic StimulationCognitionHumansTreatment OutcomeAlzheimer's diseaseBayesian network meta-analysiscognitive functiondrug therapyrepetitive transcranial magnetic stimulation

Identifiers

PMID37088953
PMCPMC10493651
OpenAlexW4366822467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.